(TMDX) TransMedics - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 3.398m USD | Total Return: 47.8% in 12m

Stock Organ Preservation, Organ Transport
Total Rating 44
Risk 35
Buy Signal -0.99
Medical Devices -6.2
Health Care Equipment -3.7
Market Cap: 3,398m
Avg Trading Vol: 109M USD
ATR: 7.16%
Peers RS (IBD): 49.4
Risk 5d forecast
Volatility62.4%
Rel. Tail Risk-12.3%
Reward TTM
Sharpe Ratio0.89
Alpha22.09
Character TTM
Beta1.317
Beta Downside-0.508
Drawdowns 3y
Max DD67.79%
CAGR/Max DD0.13
EPS (Earnings per Share) EPS (Earnings per Share) of TMDX over the last years for every Quarter: "2021-03": -0.29, "2021-06": -0.39, "2021-09": -0.47, "2021-12": -0.46, "2022-03": -0.38, "2022-06": -0.41, "2022-09": -0.25, "2022-12": -0.21, "2023-03": -0.08, "2023-06": -0.03, "2023-09": -0.78, "2023-12": 0.12, "2024-03": 0.35, "2024-06": 0.35, "2024-09": 0.12, "2024-12": 0.19, "2025-03": 0.7, "2025-06": 0.92, "2025-09": 0.66, "2025-12": 0.051, "2026-03": 0,
EPS CAGR: 20.99%
EPS Trend: 63.5%
Last SUE: -2.28
Qual. Beats: 0
Revenue Revenue of TMDX over the last years for every Quarter: 2021-03: 7.053, 2021-06: 8.171, 2021-09: 5.37, 2021-12: 9.668, 2022-03: 15.88, 2022-06: 20.521, 2022-09: 25.683, 2022-12: 31.375, 2023-03: 41.554, 2023-06: 52.465, 2023-09: 66.43, 2023-12: 81.174, 2024-03: 96.85, 2024-06: 114.305, 2024-09: 108.761, 2024-12: 121.624, 2025-03: 143.537, 2025-06: 157.37, 2025-09: 143.823, 2025-12: 160.764, 2026-03: null,
Rev. CAGR: 85.39%
Rev. Trend: 94.9%
Last SUE: 0.59
Qual. Beats: 0
Risks
Technicals: volatile
Description: TMDX TransMedics March 05, 2026

TransMedics Group Inc. (TMDX) is a medical technology company focused on organ transplant therapy. The companys primary product is the Organ Care System (OCS), a portable platform that maintains donor organs outside the body under near-physiologic conditions. This technology aims to improve organ viability and expand the donor pool.

The OCS platform supports lung, heart, and liver transplants. Specific OCS applications address challenges like standard lung preservation, reanimation of donor hearts unsuitable for cold storage, and preservation of various liver types. The medical technology sector is characterized by high R&D costs and regulatory hurdles.

Beyond its devices, TransMedics offers a national OCS program, providing a comprehensive solution for organ retrieval, management, and logistics, including transportation. This business model integrates technology with service delivery to streamline the transplant process.

Further research on ValueRay can provide deeper insights into TMDXs financial performance and market position.

Headlines to Watch Out For
  • OCS product adoption expands transplant market
  • Regulatory approvals accelerate OCS device utilization
  • National OCS Program drives service revenue growth
  • Competition from alternative organ preservation methods
  • Healthcare spending trends impact transplant procedure volumes
Piotroski VR‑10 (Strict, 0-10) 6.5
Net Income: 190.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.13 > 0.02 and ΔFCF/TA 22.57 > 1.0
NWC/Revenue: 90.58% < 20% (prev 99.04%; Δ -8.46% < -1%)
CFO/TA 0.18 > 3% & CFO 192.8m > Net Income 190.3m
Net Debt (-18.7m) to EBITDA (148.5m): -0.13 < 3
Current Ratio: 7.14 > 1.5 & < 3
Outstanding Shares: last quarter (40.9m) vs 12m ago 16.24% < -2%
Gross Margin: 59.92% > 18% (prev 0.59%; Δ 5.93k% > 0.5%)
Asset Turnover: 64.67% > 50% (prev 54.91%; Δ 9.76% > 0%)
Interest Coverage Ratio: 8.80 > 6 (EBITDA TTM 148.5m / Interest Expense TTM 13.8m)
Altman Z'' 4.22
A: 0.51 (Total Current Assets 637.8m - Total Current Liabilities 89.3m) / Total Assets 1.07b
B: -0.26 (Retained Earnings -277.9m / Total Assets 1.07b)
C: 0.13 (EBIT TTM 121.3m / Avg Total Assets 936.2m)
D: 0.79 (Book Value of Equity 473.1m / Total Liabilities 595.3m)
Altman-Z'' Score: 4.22 = AA
Beneish M -0.64
DSRI: 0.63 (Receivables 84.3m/97.7m, Revenue 605.5m/441.5m)
GMI: 0.99 (GM 59.92% / 59.31%)
AQI: 5.11 (AQ_t 0.09 / AQ_t-1 0.02)
SGI: 1.37 (Revenue 605.5m / 441.5m)
TATA: -0.00 (NI 190.3m - CFO 192.8m) / TA 1.07b)
Beneish M-Score: -0.64 (Cap -4..+1) = D
What is the price of TMDX shares? As of April 01, 2026, the stock is trading at USD 99.41 with a total of 955,461 shares traded.
Over the past week, the price has changed by -8.73%, over one month by -32.37%, over three months by -18.28% and over the past year by +47.76%.
Is TMDX a buy, sell or hold? TransMedics has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy TMDX.
  • StrongBuy: 5
  • Buy: 1
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the TMDX price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 161.3 62.3%
Analysts Target Price 161.3 62.3%
TMDX Fundamental Data Overview March 29, 2026
P/E Trailing = 20.3388
P/E Forward = 45.6621
P/S = 5.6114
P/B = 8.2584
Revenue TTM = 605.5m USD
EBIT TTM = 121.3m USD
EBITDA TTM = 148.5m USD
Long Term Debt = 502.4m USD (from longTermDebt, last quarter)
Short Term Debt = 13.3m USD (from shortTermDebt, last quarter)
Debt = 469.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -18.7m USD (from netDebt column, last quarter)
Enterprise Value = 3.38b USD (3.40b + Debt 469.7m - CCE 488.4m)
Interest Coverage Ratio = 8.80 (Ebit TTM 121.3m / Interest Expense TTM 13.8m)
EV/FCF = 25.29x (Enterprise Value 3.38b / FCF TTM 133.6m)
FCF Yield = 3.95% (FCF TTM 133.6m / Enterprise Value 3.38b)
FCF Margin = 22.06% (FCF TTM 133.6m / Revenue TTM 605.5m)
Net Margin = 31.43% (Net Income TTM 190.3m / Revenue TTM 605.5m)
Gross Margin = 59.92% ((Revenue TTM 605.5m - Cost of Revenue TTM 242.7m) / Revenue TTM)
Gross Margin QoQ = 58.11% (prev 58.80%)
Tobins Q-Ratio = 3.16 (Enterprise Value 3.38b / Total Assets 1.07b)
Interest Expense / Debt = 0.71% (Interest Expense 3.35m / Debt 469.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = 95.8m (EBIT 121.3m * (1 - 21.00%))
Current Ratio = 7.14 (Total Current Assets 637.8m / Total Current Liabilities 89.3m)
Debt / Equity = 0.99 (Debt 469.7m / totalStockholderEquity, last quarter 473.1m)
Debt / EBITDA = -0.13 (Net Debt -18.7m / EBITDA 148.5m)
Debt / FCF = -0.14 (Net Debt -18.7m / FCF TTM 133.6m)
Total Stockholder Equity = 353.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 20.33% (Net Income 190.3m / Total Assets 1.07b)
RoE = 53.88% (Net Income TTM 190.3m / Total Stockholder Equity 353.2m)
RoCE = 14.18% (EBIT 121.3m / Capital Employed (Equity 353.2m + L.T.Debt 502.4m))
RoIC = 11.09% (NOPAT 95.8m / Invested Capital 864.4m)
WACC = 9.39% (E(3.40b)/V(3.87b) * Re(10.61%) + D(469.7m)/V(3.87b) * Rd(0.71%) * (1-Tc(0.21)))
Discount Rate = 10.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.46%
[DCF] Terminal Value 70.56% ; FCFF base≈133.6m ; Y1≈113.9m ; Y5≈87.9m
[DCF] Fair Price = 37.91 (EV 1.28b - Net Debt -18.7m = Equity 1.30b / Shares 34.3m; r=9.39% [WACC]; 5y FCF grow -17.88% → 3.0% )
EPS Correlation: 63.48 | EPS CAGR: 20.99% | SUE: -2.28 | # QB: 0
Revenue Correlation: 94.90 | Revenue CAGR: 85.39% | SUE: 0.59 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.76 | Chg7d=-0.018 | Chg30d=-0.088 | Revisions Net=+0 | Analysts=7
EPS current Year (2026-12-31): EPS=2.52 | Chg7d=-0.002 | Chg30d=-0.390 | Revisions Net=-4 | Growth EPS=-4.0% | Growth Revenue=+21.8%
EPS next Year (2027-12-31): EPS=3.71 | Chg7d=+0.038 | Chg30d=+0.014 | Revisions Net=+0 | Growth EPS=+46.9% | Growth Revenue=+18.7%
[Analyst] Revisions Ratio: +0.00 (2 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.7% (Discount Rate 10.6% - Earnings Yield 4.9%)
[Growth] Growth Spread = +14.5% (Analyst 20.2% - Implied 5.7%)
Additional Sources for TMDX Stock Fund Manager Positions: Dataroma · Stockcircle